ArticleMolecular biology reports2026
CSN3 promotes colorectal cancer cell progression through activation of the PI3K/AKT/mTOR pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCSN3 (κ-casein) is essential for casein micelle formation and cellular differentiation, and dysregulated CSN3 has been linked to tumorigenesis. However, its role in colorectal cancer (CRC) remains unclear. METHODS AND
resultsCSN3 expression in CRC was evaluated using GEO and TCGA datasets, immunohistochemistry, and qRT-PCR. Its biological functions were investigated using gain- and loss-of-function approaches combined with CCK-8, apoptosis, wound-healing, and Transwell assays. Transcriptomic analysis of the GEO dataset GSE21510 was used to identify CSN3-associated signaling pathways, which were further investigated by western blotting, RT-qPCR, co-immunoprecipitation (Co-IP), AKT inhibition, and CSN1S1 knockdown rescue experiments. CSN3 was significantly upregulated in CRC tissues and was associated with lymph node metastasis, advanced TNM stage, and poor prognosis. Functionally, CSN3 overexpression promoted CRC cell proliferation, migration, and invasion while suppressing apoptosis, whereas CSN3 knockdown produced the opposite effects. CSN3 also promoted epithelial-mesenchymal transition (EMT). Mechanistically, enrichment analysis and western blotting demonstrated that CSN3 activated the PI3K/AKT/mTOR signaling pathway, accompanied by increased phosphorylation of PI3K, AKT, mTOR, p70S6K, and 4EBP1. MK-2206 attenuated CSN3-induced proliferation, migration, invasion, and EMT, partially restored apoptosis, and reduced AKT phosphorylation. STRING and Co-IP supported an association between CSN3 and CSN1S1. CSN1S1 knockdown attenuated CSN3-induced proliferation, migration, invasion, EMT, and AKT activation.
conclusionsCSN3 promotes malignant CRC cell phenotypes partly through AKT signaling, with CSN1S1 contributing to CSN3-mediated AKT activation and tumor-promoting effects, suggesting potential prognostic relevance in CRC.
Indexed as
Identifiers
42821034What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.